Metraipolis › archive › dc_2d090eee730e

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma — Europe PMC PMID:41853402

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41853402
DOI: 10.7759/cureus.103648
License (as archived): solo-consultazione
Archived: 2026-11-05T19:26:14.947Z
SHA-256 of the archived text: f1bfca68ee6fb79f24f4ef5ed12c55e25ce237d1966a809f8cf53ba075e07fec
Stable URL of this page: https://metraipolis.com/documento/dc_2d090eee730e

How to cite

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma — Europe PMC PMID:41853402 — Europe PMC (en), https://europepmc.org/article/MED/41853402 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d090eee730e (Metraipolis archive dc_2d090eee730e, sha256 f1bfca68ee6fb79f24f4ef5ed12c55e25ce237d1966a809f8cf53ba075e07fec)

BibTeX

@misc{dc2d090eee730e,
  title = {Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma — Europe PMC PMID:41853402},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41853402},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d090eee730e; sha256 f1bfca68ee6fb79f24f4ef5ed12c55e25ce237d1966a809f8cf53ba075e07fec},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41853402. Agents can read the archived copy with the MCP tool read_document.